Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Geron Corp GERN

Alternate Symbol(s):  GERNW

Healthcare Biotechnology
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the... see more

Recent & Breaking News (NDAQ:GERN)

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire October 19, 2023

Geron Announces EMA Validation of Marketing Authorization Application for Imetelstat for the Treatment of Lower Risk MDS

Business Wire September 29, 2023

Geron Announces Appointment of Michelle Robertson as Executive Vice President, Chief Financial Officer and Treasurer, and the Retirement of Olivia Bloom, Geron's Long-Time Chief Financial Officer

Business Wire September 11, 2023

Geron Announces Data Presentations from IMerge Phase 3 Evaluating Imetelstat in Lower Risk MDS at Society of Hematologic Oncology Annual Meeting

Business Wire September 7, 2023

Geron to Participate in the Baird 2023 Global Healthcare Conference

Business Wire September 5, 2023

Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS

Business Wire August 22, 2023

Geron Announces FDA Acceptance of New Drug Application for Imetelstat for the Treatment of Lower Risk MDS

Business Wire August 21, 2023

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire August 17, 2023

Geron Corporation Reports Business Highlights and Second Quarter 2023 Financial Results

Business Wire August 3, 2023

Geron to Announce Second Quarter 2023 Financial Results on August 3, 2023

Business Wire July 27, 2023

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 20, 2023

Geron Announces U.S. Expanded Access Protocol for Imetelstat in Lower Risk MDS

Business Wire June 29, 2023

Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Business Wire June 22, 2023

Geron Announces Submission of New Drug Application to FDA for First-in-Class Telomerase Inhibitor Imetelstat

Business Wire June 20, 2023

Geron Announces First Patient Dosed in Investigator-Led Phase 2 IMpress Trial Evaluating Imetelstat in Patients with Relapsed/Refractory AML or Higher Risk MDS

Business Wire June 13, 2023

Geron Announces New Data and Analyses from IMerge Phase 3 Presented at EHA Reporting Robust Durability of Transfusion Independence, Evidence of Disease-Modifying Activity and Favorable Fatigue PRO in Imetelstat-Treated Lower Risk MDS Patients

Business Wire June 12, 2023

Geron to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

Business Wire June 7, 2023

Geron to Host Virtual Investor Event on June 14, 2023

Business Wire June 6, 2023

Geron Announces ASCO Presentation Reporting Durable Continuous Transfusion Independence with Imetelstat in IMerge Phase 3 Lower Risk MDS Patients

Business Wire June 2, 2023

Geron Oral Presentation at Upcoming ASCO Annual Meeting to Highlight Meaningful Continuous Transfusion Independence Observed in Imetelstat-Treated Lower Risk MDS Patients in IMerge Phase 3

Business Wire May 25, 2023